Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an agreement to purchase Caraway Therapeutics, a US-based pre-clinical company, for a potential total of USD 610 million, which includes upfront and milestone payments. This acquisition will enhance MSD’s portfolio with a range of small-molecule candidates targeting neurodegenerative and rare diseases. These candidates are designed to modulate lysosomal function, aiming to clear toxic materials and cellular components, a mechanism with potential disease-modifying capabilities.
Caraway Therapeutics’ Background and Investor Support
As per the press release, Caraway’s investor roster includes notable pharmaceutical companies such as AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), and Eisai (TYO: 4523), with MSD having been an investor since 2018. This acquisition underscores the industry’s confidence in Caraway’s approach to addressing unmet needs in neurodegenerative and rare disease treatment.- Flcube.com
